Introduction
restriction indeed delays the onset of end-stage renal disease [1] . Evidence also suggests that dietary protein restriction A series of meetings on Proteinuria and Progressive retards the progression of diabetic renal disease as well [2] . Renal Disease has been conducted over the past few The Modification of Diet in Renal Disease Study, a large years in Paris (1992) , Vienna (1994) , Amsterdam multicenter clinical trial also demonstrates a benefit of dietary (1996) The proceedings of the fourth meeting are organized patients with diabetic and non-diabetic chronic renal disease as extended abstracts, and provide a overview of the [4, 5] . different approaches towards progressive renal disease, Among diabetics, randomized multicenter clinical trials both in diabetic and non-diabetic nephropathy.
have examined the merits of ACE inhibitors in both type 1 Special attention is given to the concept of micro-and type 2 patients. Evidence in support of a strong renoproalbuminuria, with special reference to early treatment, tective effect of this class of antihypertensive therapy was within the area of diabetes. obtained in those with already overt nephropathy as well as in those with incipient nephropathy [4, 6 ] . Based on these
The organizers warmly thank the sponsors of the Progression of renal disease meta-analysis. Br Med J 1992; 304: 216-220 Barry Brenner; Renal Division, Brigham and Women's 2. Zeller K, Whittaker E, Sullivan L, Raskin P, Jacobson HR. Effect Hospital and Harvard Medical School, Boston, MA of restricting dietary protein on the progression of renal failure in patients with insulin-dependent diabetes mellitus. N Engl J Med Glomerular hypertension has been implicated as a major 1991; 324: 78-84 factor in mediating progressive renal damage after any of a 3. animals have begun to be tested in humans. Dietary protein 1996; 334: 939-945 restriction and antihypertensive drug therapy have been the 6. Viberti G, Mogensen CE, Groop LC, Pauls JF. Effect of captopril principal therapeutic interventions tested thus far. A metaon progression to clinical proteinuria in patients with insulinanalysis of studies of low-protein diets in renal insufficiency, dependent diabetes mellitus and microalbuminuria . JAMA 1994; 271: 275-279 and side chains in human glomerular diseases. Kidney Int 1993; rises within the normal range. This observation raises the 43: 454-463 possibility that elevated pressure levels may be one important 6. Van Bruggen MCJ, Kramers K, Hylkema MN et al. Decrease factor contributing to the development of renal damage. of heparan sulfate in the glomerular basement membrane in Indeed, diabetic nephropathy clusters in families and diabetic murine lupus nephritis. Am J Pathol 1995; 146: 753-763 patients who develop albuminuria belong to families with a 7. Kramers C, Hylkema MN, Van Bruggen MCJ et al. Anti-higher prevalence of arterial hypertension and cardiovascular nucleosome antibodies complxed to nucleosomal antigens show disease. Of interest diabetic patients with microalbuminuria anti-DNA reactivity and bind to rat glomerular basement memare more insulin-resistant than patients with normal albumin brane in vivo. J Clin Invest 1994; 94: 568-577 excretion rate and this may explain why patients with mic- N Engl J Med 1992; 326: 673-677 type 2 disease, have evidence of salt retention as shown [15] and 2 diabetic patients required more than one antihypertensive drug for optimal control of blood pressure [23] . by increased plasma atrial natriuretic peptide and reduced plasma aldosterone and renin concentrations [1] . These Given the complex nature of diabetes, these findings raise the important question as to which combination therapy will propatients also have enhanced vascular responsiveness to exogenous administration of catecholamines and angiotensin II vide the optimal antihypertensive, renal and metabolic effects.
Although an ACE inhibitor plus a low dose diuretic is a (AII ) [2] . Elevated plasma concentrations of these hormones and serum angiotensin converting enzyme (ACE) activity, popular choice of therapy, the combination of an ACE inhibitor and a calcium channel blocking agent has potential suggesting activation of these hormonal systems, have also have been reported [1] . On the other hand, reduced natriur-additional advantages. Calcium channel blocking agents are potent antihypertensive agents given either alone or in cometic responses, such as reduced urinary dopamine excretion, may also contribute to this salt-retaining tendency [3] . In bination with an ACE inhibitor [24, 25] especially in patients with salt retention [26 ] , such as diabetic [27] and elderly accord with this pathophysiological heterogeneity, different classes of antihypertensive drugs with different modes of patients [28] . In some patient groups, such as those with young age or suboptimal metabolic control, a calcium chanactions have been shown to be effective in reducing blood pressure in diabetic patients, albeit also with marked hetero-nel blocking agent may be a preferred agent given the potential adverse effects of a diuretic such as those on intermediary geneity in treatment responses [4] . The latter is further influenced by potential inter-ethnic pharmacokinetic and metabolism and sexual dysfunction, albeit small and doserelated [13] . Despite the extensive clinical use of calciumpharmacodynamic differences [5, 6 ] .
Hypertension and proteinuria frequently coexist in type 2 channel blocking agents, the renal effects of this class of agents remain controversial [29] . Although the dihydropyriddiabetic patients, especially in non-Caucasian populations [7] . The coexistence of these two conditions markedly ine calcium-channel blocking agents, such as nifedipine and amlodipine, may increase proteinuria due to their dilating increase the risk of cardiovascular death and renal failure in these patients. The pathogenesis of diabetic proteinuria is effects on both afferent and efferent glomerular arterioles, their beneficial effects on GFR due to a reduction of systemic complex and involves vascular (systemic and intraglomerular hypertension), metabolic (hyperglycaemia and hyperlipidae-blood pressure should be taken into consideration [29] .
Despite the potential cardioprotective effects of blocking mia), growth and genetic factors [8] . However, control of glycaemia [9] and blood pressure [10] are two of the most agents [30] and the beneficial effects of blocking agents on insulin resistance [12] , there are no long-term studies examinpowerful determinants for the progression of proteinuria. In patients with clinical proteinuria and established renal dis-ing the use of these agents in type 2 diabetic patients. On the other hand, the new class of antihypertensive agent, the AII ease, adequate control of blood pressure is of paramount importance [10] . As shown in one of the meta-analyses, a type 1 receptor antagonist, such as losartan, has been shown to reduce proteinuria more effectively than a calcium-channel reduction of mean arterial pressure of 10 mmHg is accompanied by an increase of 3.7 ml/min/year of glomerular filtration blocking agent despite similar, and in some patients, less reduction in blood pressure [31] . There is now an ongoing rate (GFR) [4] . However, since proteinuria and GFR are also determined by metabolic factors such as hyperglycaemia and 4-year study, the RENAAL (Reduction in Endpoints in NIDDM with AII Antagonist, Losartan) Study, which examhyperlipidaemia [11] , the metabolic effects of antihypertensive agents may influence their renal effects. In this respect, in ines the renoprotective effects of losartan versus placebo in type 2 diabetic patients with macroalbuminuria and renal view of their relatively neutral effects on carbohydrate and lipid metabolism, ACE inhibitors and calcium channel impairment. However, more studies are needed to define the optimal antihypertensive regimen in type 2 diabetic patients blocking agents are frequently used as first line antihypertensive agents in diabetic patients [12] [13] [14] .
who make up the majority of patients with renal failure. In this respect, a randomized, parallel study examining the comThere is now a wealth of data confirming the antiproteinuric effects of ACE inhibitors in both type 1 and type bination of an ACE inhibitor with a low-dose diuretic or a calcium channel blocking or an AII receptor antagonist on 2 diabetic patients, an effect which is independent of blood pressure reduction [4] . The use of this class of drug has also vascular, renal and metabolic indices as well as clinical endpoints will be of particular interest and major therapeutic been shown to reduce the rate of decline in renal function in type 1 [15] , normotensive type 2 diabetic [16, 17] as well as relevance. non-diabetic patients with chronic renal failure [18, 19] . Although there are sufficient reasons to believe that these 1993; 118: 129-138 In the first 12 months, the rate of decline in GFR correlated 5. Zhou HH, Koshakji RP, Silbertstein DJ, Wilkinson GR, Wood with the reduction in blood pressure. This was followed by a AJJ. Racial differences in drug response. Altered sensitivity to stabilisation of GFR which correlated inversely with the and clearance of propranolol in men of Chinese descent as reduction in blood pressure [23] . These findings further compared to American whites. N Engl J Med 1989; 320: 565-570 emphasise the importance of conducting long term studies in 6 In nearly all studies prospectively evaluating the develop- 1996; 156: 286-289 ment and progression of diabetic nephropathy, the diabetic 18. The GISEN Group. Randomised placebo-controlled trial of patients who progress to nephropathy have higher haemoeffect of ramipril on decline in glomerular filtration rate and globin A1c values than those diabetic patients who did not risk of terminal renal failure in proteinuric, non-diabetic nephro-advance [3, 4] . Thus it is difficult to demonstrate the independ- [5] . This relationship was most easily filtration rate in non-insulin-dependent diabetic patients. Am shown in the standard treatment group, with similar trends The presence of clinical albuminuria (>300 mg/24 h) indiangiotensin converting enzyme inhibition with captopril in the cates a clear risk for renal failure. The rate at which the therapy of patients with severe primary hypertension. Circulation glomerular filtration rate falls in patients with clinical diabetic 1984; 70: 279-284 nephropathy has been reduced with careful implementation from pancreas transplantation indicate optimal glycemic con-1]: S161-S164 27. Chan JCN, Nicholls MG, Cheung CK, Law LK, Swaminathan trol may require several years before efficacy may be demonAbstracts 1062 production, glycemic control and prevalence of microvascular strated [7, 8] . However, with careful implementation of lesions and polyneuropathy in long-term type 1 (insulin-dependtherapeutic modalities to improve glycemic control and to ent) diabetes mellitus. Diabetologia 1987; 30: 208 control hypertension, kidneys of diabetic patients may experience many more years of function before failing.
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In the practice of diabetes care basal insulin secretion or its replacement with long-acting insulin enables efforts to approach near-normal glycaemia. Yet in most type 1 diabetic Preservation of normal GFR in type 1 diabetic patients with patients the clear benefit of a sustained level of basal insulin microalbuminuria under long-term (8 years) ACE inhibition secretion (usually indicated by a rise in c-peptide levels followElisabeth R. Mathiesen, Eva Hommel, Henrik P. Hansen, ing mixed meal stimulation) cannot be duplicated by exogenHans-Henrik Parving; Steno Diabetes Center, Gentofte, ous insulin therapy [9] . The DCCT Research Group Denmark demonstrated that intensive glycaemic control extends the time of demonstrable islet function [10] .
The aim was to asses the long term effectiveness of angioThe DCCT Research Group also reported a lower risk for tensin converting enzyme inhibition on preservation of glomof retinopathy and nephropathy for those patients with resid-erular filtration rate (GFR) in type 1 diabetic patients with ual islet function who received intensive therapy compared to microalbuminuria. Forty-four normotensive insulin dependintensively treated patients with no residual islet function. Of ent diabetic patients with persistent microalbuminuria (uringreat interest was the accompanying reduced risk of hypogly-ary albumin excretion ( UAE) 30-300 mg/24 h) were enrolled caemia in those DCCT subjects with sustained c-peptide in an open randomized controlled study of 8 years duration. secretion receiving intensive treatment. Thus uniquely in The treatment group (n=21) was given captopril (50 mg those patients with residual islet function the reduced risk of b.i.d.) and low-doze thiazide. The remaining 23 patients were the microvascular complications was accompanied by a lower left untreated unless hypertension did develop (n=4). All risk of hypoglycaemia. except 2 patients from each group completed the 8-year In general those patients who may more successfully reach follow-up. Sixteen of the 19 patients in the treatment group the goals of intensive therapy have an older age of onset and and 2 patients from the control group were subsequently are more likely to retain higher levels of c-peptide secretion investigated before and 2 months after cessation of antihyperand thus sustained islet function.
tensive treatment. The percentage of patients progressing to nephropathy was 40% (9/23) in the control group and 10% (2/21) in the intervention group (P<0.02). During the pause and −3.5 (3) ml/min (NS) in the 6 patients from the capto-4. Microalbuminuria Collaborative Study Group. Risk factors for pril group with UAE >300 mg/24 h during the treatment the development of microalbuminuria in insulin-dependent dia-pause (P<0.01 between the groups).
betic patients: a cohort study. Br Med J 1993; 306: 1235 -1239 Conclusion. The beneficial effect of angiotensin converting The Microalbuminuria Captopril Study Group. Captopril reduces Analysis of the influence of ACE inhibition on the well known the risk of nephropathy in IDDM patients with microalbuminuria. risk factors for the progression of renal disease demonstrates Diabetologia 1996; 39: 587-593 a very modest reduction of mean blood pressure, below statistical significance; a modest decline in plasma total and LDL cholesterol and no change in HDL and HbAlc values. The most important effect of ACE inhibition therefore remains the reduction in albuminuria. These results may therefore be Long-term studies in NIDDM. Effects on nephropathy and interpreted as supporting the major role of albuminuria in the retinopathy progression of renal disease. We have examined the protectMordchai Ravid, Yosefa Bar-Dayan, Zohar Levi, David ive effect of ACE inhibitors also in the very-low-risk group of Brosh, Dont Ravid-Safran, Rita Rachmani; Department of normotensive-normoalbuminuric patients with NIDDM. Medicine, Meir Hospital, Kfar-Sava and Sackler Faculty of Six-year follow-up on 156 patients, randomized to receive Medicine, Tel-Aviv University, Israel enalapril or placebo showed a modest but a significant effect of enalapril on attenuation of the decline in creatinine clearThe last decade of the 20th century has witnessed a marked ance and on albuminuria. The mean decrease in creatinine increase in the incidence of diabetes mellitus, mainly of the clearance was 2.5 ml/min/year in the placebo group and l.5 non-insulin-dependent variety. This and the rise in life expectm1/min/year in those who received enalapril (P=0.040). The ancy forecast a major load of end-stage renal disease on the institution of enalapril treatment was followed by an initial health-care systems of the industrial as well as some developdecline in creatinine clearance of about 3 ml/min. Subsequent ing countries. Effective policies to attenuate the progress of follow up showed stabilization throughout the trial period. diabetic nephropathy are therefore of increasing importance.
The difference between the placebo and the treated arms, There is a general agreement about the impact of hypertentherefore became significant only after 5 years. There was a sion on the pace of deterioration in kidney function and of significant association between the initial decline in UAE rate the importance of albuminuria both as a prognostic paraby ACE inhibition and the subsequent renoprotective effect. meter and as a contributing factor to disease progression.
15/79 placebo treated and 5/77 enalapril treated patients There is no consensus however about the desired levels of crossed the threshold to microalbuminuria (P=0.042). blood pressure or about the link between decrease in urinary
The presence of diabetic retinopathy was recorded by an albumin excretion ( UAE) and the extend of renoprotection.
annual ophthalmoscopic examination. In diabetics with Also the relative efficacy of the various therapeutic regimes microalbuminuria, there were fewer new cases of retinopathy remains unsettled.
among those treated with enalapril: (7.8 vs 19% among the ACE inhibitors are advocated by some researchers as the placebo group patients over a period of 5 years). Among the preferred agents for renoprotection. Others, however, show normoalbuminuric patients fewer new cases of retinopathy similar effects on the kidney also of calcium channel blocking were found in those treated with enalapril: (6%-new cases agents and of beta blocking drugs [1] [2] [3] . Meta-analysis of the among enalapril-treated vs 17.8% in the placebo group during various therapeutic trials is a frustrating task due to major 6 years). When pulled together there were 2794 patient-years discrepancies in baseline characteristics of the patients especiof follow-up. Enalapril treatment resulted in an absolute risk ally in terms of risk factors (e.g control of hyperglycaemia, reduction of 11.5 percentage points for the development of lipid profile, age, duration of diabetes) and trial design. Some retinopathy (95% CI 6-27, P=0.004). There were very few studies include patients with and without nephropathy, with patients with proliferative retinopathy and this development and without hypertension and one or both types of diabetes.
seemed to be independent of therapy. The results of both Furthermore, in studies of similar design the results are divertrials indicate that the introduction of ACE inhibitor therapy gent largely due to differences in surrogate end-points, choice may have a long-term protective effect on the microvascular and dosage of therapeutic agents and duration of the study disease of diabetes also in low-risk patients. In the kidney, the [4] [5] [6] .
main ACE inhibitor induced modification is the decline in Long-term studies in NIDDM have shown a varying albuminuria. The protection of the retinal blood vessels may degree of decline in GFR in hypertensive and normotensive be partially due to the low blood pressure and possibly also patients with nephropathy which was partially attenuated by by direct effects on the capillary wall. ACE inhibitors and by calcium blockers. The short-term studies, lasting 1 year or less have often failed to demonstrate significant change in kidney function, and therefore also no l. The studies we have performed are of 5 and 6 years dura- 305: 981-985 tion. The patient population was uniform and they were 3. Melbourne Diabetic Nephropathy Study Group. Comparison placebo controlled [7] . We therefore believe that our results between perindopril and nifedipine in hypertensive and normoare reliable. They represent, however, highly selected groups tensive diabetic patients with microalbuminuria. Br Med J 1991; 302: 210-216 of patients low and very low risk. The extrapolation of our
results to the diabetic population at large may therefore be with either enalapril or nitrendipine stabilizes albuminuria and problematic. The effect of a given therapeutic intervention is increases glomerular filtration rate in non-insulin-dependent diaexpected to correlate to the degree of risk of the treated betic patients. Am J Kidney Dis 1994; 24: 753-761 patients. The finding of a beneficial effect in a low-risk group 5 to normoalbuminuria compared to 6 patients (21%) in the Urinary albumin excretion rate (AER) was centrally assessed placebo group (P<0.01). by two overnight urine collections at baseline, 6, 12, 18 and In the subgroup of patients examined in Aarhus (n=22) we 24 months. Retinal photographs were taken at entry and 24 performed 24-h ambulatory blood pressure measurements months, and graded into 5 groups ('none' to 'proliferative').
(AMBP), renal function tests (constant infusion technique) At 2 years, AER was 18.8% lower in the lisinopril compared and determinations of exercise-induced albuminuria (bicycle to placebo group (95% CI 2.0, 32.7, P=0.03), adjusted for baseline AER and centre; absolute difference 2.2 g/min.
ergometer, 70% of estimated maximal VO 2 ). AMBP showed In people with normoalbuminuria, the treatment difference small increases in 24-h systolic and diastolic AMBP (1.6±6.2 was 12.7% (95% CI−2.9, 26.0, P=0.1), absolute difference and 0.7±4.9 mmHg over 2 years) in the placebo group, as 1.0 g/min, whilst in those with microalbuminuria, this differ-opposed to significant reductions in the lisinopril group ence was 49.7% (95% CI−14.5, 77.9, P=0.1), absolute (−6.0±8.2 and −4.1±6.4 mmHg), (P<0.02 and 0.05 difference 34.2 mg/min (P=0.04 for interaction). Retinopathy between the values)). Clinic BP measurements did not show progressed by at least one stage in 13% of the lisinopril group significant differences. There were no differences in GFR or and in 24% of the placebo group (P=0.02). Lisinopril also RPF in the two groups, but development in UAE and develreduced progression to proliferative retinopathy, odds ratio opment in filtration fraction (FF ) was positively correlated 0.18 95% CI 0.04, 0.82, P=0.03. Treatment reduced retinopa-in the intervention group (r=0.9, P>0.01), i.e. the patients thy incidence, odds ratio 0.69, 95% CI 0.30, 1.59, P=0.4. who showed the greatest fall in UAE also were the ones with Lisinopril slows the progression of renal disease in normot-the greatest fall in FF. Exercise testing showed a numerically ensive type 1 diabetic patients with little or no albuminuria, reduced increase in exercise induced albuminuria in the lisinobut the greatest effect was observed in those with micro-pril group compared to the placebo group, although the albuminuria (AER 20 g/min). Lisinopril also reduces the difference was not statistically significant. risk of progression of retinopathy. The use of ACE inhibitors
In conclusion, ACE-i treatment in patients with low-grade should be considered in the early stages of type 1 diabetes. Diabetologia 1994; 37: 788-796 treated with cilazapril or amlodipine [8] . The rate of GFR Østerby R, Bangstad HJ, Nyberg G, Walker JD, Viberti GC. A fall in the study group as a whole was inversely related to the quantitative ultrastructural study of juxta glomerular arterioles in decrease in mean blood pressure, suggesting that arterial IDDM patients with micro-and normoalbuminuria. Diabetologia hypertension modulates the progression of renal damage, 1995; 38: 1320-1327 even when AER is normal. A 12 month comparison of enalaBangstad HJ, Østerby R, Dahl Jørgensen K, Berg KJ, Hartmann A, pril and nitrendipine in 16 microalbuminuric type 2 diabetic Nyberg G, Bjørn SF, Hanssen KF. Early glomerulopathy is prepatients with biopsy-proven DN showed that AER was sent in young, type 1 (insulin-dependent) diabetic patients with stabilized and GFR increased in both groups [9] . After 27 microalbuminuria. Diabetologia 1993; 36: 523-529 Poulsen PL, Ebbehøj E, Hansen KW, Mogensen CE. 24-h blood months, AER decreased in both groups compared to baseline pressure and autonomic function is related to albumin excretion and GFR remained at or above baseline levels in both groups.
within the normoalbuminuric range in IDDM patients.
A recent study in type 2 diabetic patients examined the patients had a greater rate of decline in creatinine clearance and a lesser fall in AER. However, no differences were discerned between the ACEi and CCB groups. In a 42 month study from Denmark, hypertensive type 2 diabetic patients Ace inhibition vs calcium-channel blockade in normotensive with DN were treated with lisinopril (n=21) or atenolol (n= type 1 and type 2 diabetic patients with microalbuminuria 22), in equihypotensive doses. After 6 months, GFR declined by less than 1 ml/min/month in both groups suggesting that G. Jerums on behalf of the Melbourne Diabetic Nephropathy the progressive decline in GFR in DN can be ameliorated Study Group, Melbourne, Australia equally effectively by both treatments even though AER was Several studies have examined whether angiotensin con-reduced more in the lisinopril than the atenolol group [11] . verting enzyme inhibitors (ACEi) exert beneficial effects on
In 1991, the Melbourne Diabetic Nephropathy Study the course of diabetic nephropathy (DN ) which extend Group reported the results of 12 months of treatment with beyond blood pressure control. In type 1 diabetes, such an equihypotensive doses of perindopril or nifedipine (slow effect has been demonstrated in patients with advanced DN release) in type 1 and type 2 diabetic patients with microalbu-[1] and the antiproteinuric effect of ACEi has been linked to minuria [12] . Both treatments reduced AER in hypertensive subsequent protection from a decline in glomerular filtration patients and stabilised AER in normotensive patients. A rate (GFR) [2] . However, in normotensive microalbuminuric second study is now in progress, with a follow-up of patients it has been difficult to determine if the initial decline 2-8 years, in normotensive microalbuminuric (AER in albumin excretion rate (AER) is linked to protection from 20-200 g/min in 2 out of 3 measurements) patients with type the subsequent decline in GFR, even after a follow-up of 8 1 or type 2 diabetes. Entry systolic blood pressure (SBP) was years [3] .
<140 mmHg if age <40 years, otherwise <160 mmHg and The renal effects of ACEi in overt DN have been compared diastolic blood pressure (DBP) <90 mmHg. Eighty-one with those of other antihypertensive agents by meta-analysis. patients were randomly assigned to receive placebo (PLAC ), ACEi were shown to decrease proteinuria independently of perindopril (PER) or nifedipine (NIF ) using an open label changes in blood pressure and had an additional favourable protocol. Perindopril 2-8 mg/day and nifedipine (slow effect on GFR that was independent of changes in blood release) 10-40 mg/day were titrated to achieve a fall in DBP pressure. ACEi and calcium-channel blockers (CCB) other >4 mmHg. In each participant, mean SBP, DBP and MBP than nifedipine had very similar renal protective effects, during the study, and gradients in AER (% change/year), and expressed as changes in proteinuria or GFR, whereas nifedip-calculated GFR (Cockcroft-Gault, ml/min/year), were calcuine therapy did not reduce proteinuria and was associated lated from 3 monthly measurements. The development of with a more rapid decline in GFR [4] . macroalbuminuria was noted. In addition, yearly measureIt is not clear to what extent studies in type 1 diabetes can ments of GFR using 99mTechnetium-DTPA and 24-h be translated to type 2 diabetic patients. In type 2 diabetes, ambulatory blood pressure were performed. ACEi has been shown to reduce AER and to present a decline
In both type 1 and type 2 diabetic patients, HbA1c levels in GFR as estimated on the basis of the reciprocal of plasma were not significantly different in any treatment group. creatinine levels, when studied over 7 years in middle-aged
In the 47 type 2 diabetic patients, mean clinic arterial presIsraeli subjects [5] . A similar study performed over 4 years in sure during the study was similar in the 3 groups (PER 98, normotensive Japanese type 2 diabetic patients, showed that NIF 97, PLAC 100 mmHg). However, mean 24-h ambulatACEi reduced AER but did not change creatinine clearance ory blood pressure was lower in perindopril treated patients [6 ] .
(PER 90, NIF 100, PLAC 97 mmHg, PER vs NIF P<0.05). Several recent studies have directly compared CCB with Baseline AER levels were: PER 96, NIF 60, PLAC 86 g/min, ACEi in evolving DN. In normotensive type 1 microalbumin-n.s. Individual AER gradients showed no tendency to uric patients, a placebo-controlled study compared the effects increase in any treatment group (PER−4, NIF −1, PLAC of lisinopril and nifedipine over 4-10 years [7] . Both drugs +4%/year, n.s.). Eleven patients developed macroalbuminuwere equally effective in delaying the occurrence of overt pro-ria (PER 2, NIF 3, PLAC 6, n.s.). Mean baseline GFR was teinuria, despite lower systolic blood pressure levels in the similar in all three groups (PER 116, NIF 110, PLAC lisinopril-treated group. In a 3-year study of 44 hypertensive 119 ml/min/1.73 m2, n.s.). Individual GFR gradients in the placebo group showed a significant downward trend type 2 diabetic patients with normo-or microalbuminuria, a Diab Med 1996; 13: 120-124 (PER +1 approximated to 100 ml/min/1.73m2 in all three treatment 302: 210-216 groups. Calculated GFR was generally lower than measured GFR and declined by approximately 3 ml/min/year, with no evidence of an accelerated rate of decline in the nifedipine group.
In summary, no evidence of progression of AER or GFR Long term follow-up of the glomerular filtration rate in was noted in microalbuminuric type 2 diabetic patients who normotensive type 1 diabetic subjects with microalbuminuria remained normotensive or whose blood pressure was main-during angiotensin 1 converting enzyme inhibition tained below 160/90 after a mean follow-up of 4 years. No Michel Marre, Patrick Fabbri, Béatrice Bouhanick, Gilles specific renoprotective effect of perindopril or nifedipine Berrut, Jean-Jacques Le Jeune, Françoise Bled; Centre could be demonstrated. By contrast, in type 1 diabetic Hospitalier Universitaire, 49033 Angers Cedex 01, France patients, AER did increase significantly in the placebo and nifedipine groups, and this was prevented by perindopril. Objectives. The glomerular filtration rate can be protected by Definitive assessment of the effects of nifedipine and perindo-angiotensin I converting enzyme inhibition in subjects who pril on progression of GFR will require longer-term study as develop diabetic nephropathy. Diabetic nephropathy (indiwell as further assessments of GFR by: (a) calculation of cated by proteinuria, or macroalbuminuria, >300 mg/24 h) GFR gradients weighted for duration of therapy to allow for can be prevented by angiotensin I converting enzyme inhibiunequal follow up; (b) calculation of GFR gradients with tion in normotensive type 1 diabetic subjects with microand without baseline values to allow for initial treatment albuminuria (30-300 mg/24 h). However, the glomerular fileffects on GFR; (c) measurement of GFR after cessation of tration rate is normal or supranormal in these patients. We drug therapy.
therefore tested the value of early angiotensin I converting If an effect of either drug on GFR progression is found, it enzyme inhibition to maintain the glomerular filtration will then be necessary to determine if this can be separated rate of normotensive type 1 diabetic subjects with microfrom an effect on systemic blood pressure. Current evidence albuminuria in the long term. suggests that clinic blood pressures may be an unreliable Design. Prospective, open, sequential, follow-up study of the indicator of 24-h ambulatory blood pressure levels in normot-glomerular filtration rate in normotensive type 1 diabetic subensive patients.
jects with microalbuminuria receiving one of two treatment strategies with an angiotensin I converting enzyme inhibitor 1. Lewis (>150 ml/min/1.73 m2, the mean plus 2 SD of 36 controls), 6 . Sano T, Hotta N, Kawamura T et al. Effects of long-term enalapril treatment on persistent microalbuminuria in normot-normofiltration (99-150 ml/min/1.73 m2), or hypofiltration Table 1 . Glomerulopathy data, mean and (CV%) (<99 ml/min/1.73 m2, the mean minus 2 SD of controls). The primary outcome measure was the number of subjects who progressed to glomerular hypofiltration. filtration, and 9 normofiltration, whereas 3 subjects on
strategy 2 had hyperfiltration, and 7 normofiltration (n.s.). At follow-up, 8 subjects on strategy 1 had hyperfiltration, and 7 normofiltration, whereas one subject on strategy 2 had hyperfiltration, 4 normofiltration, and 5 hypofiltration (x2=10.69; volume fractions but the results in terms of change from first P<0.01). On strategy 1 the median rate of change in the glo-to second biopsy were quite similar by EM and LM. merular filtration rate was 0.03 vs −0.86 ml/min/1.73 m2/ In a subset of the patients (six pair-biopsies) a comparison month of follow-up on strategy 2 (Mann-Whitney U test of results was made using either three or five glomeruli. The P=0.0016). These results were attributable to the enalapril conclusion concerning paired biopsies did not change with treatment strategy but not to changes in blood pressure, or to the larger number studied. final status of urinary albumin excretion.
In the baseline biopsies the type 1 diabetic group of patients Conclusions. Treatment with enalapril (20 mg/24 h) prevents had significantly increased structural parameters compared the glomerular filtration rate declining in normotensive type with the control group (see Table 1 ). Each of the parameters 1 diabetic subjects with microalbuminuria.
showed normo-and low-grade albuminuria. This discrepancy can probably be ascribed to the fact that all of our patients were young with microalbuminuria appearing after 10-15 years of diabetes and none had hypertension. It seems that when microalbuminuria appears after longer duration of diabetes and Structural changes in microalbuminuria, effect of intervention patients' age thus is higher, a different pattern of the Ruth Østerby, Hans-Jacob Bangstad, Susanne Rudberg; structural changes is seen [3] , probably dominated by Electron Microscopy Laboratory, Aarhus Kommune-macroangiopathy. hospitalet, Aarhus University Hospital, Aarhus, Denmark;
The study dealing with the effect of intensified diabetes Aker Diabetes Research Centre, Aker University Hospital, treatment [4] showed positive correlation between mean Oslo, Norway; Pediatric Unit, Karolinska Instituttet, HbA 1c during the study and increase in basement membrane Stockholm, Sweden thickness (BMT ) (r=0.70, P=0.001). Thus, although optimal diabetes control was not achieved in these adolesTwo follow-up biopsy series have been obtained in microalbuminuric type 1 diabetic patients with the aim of testing the cents, the patients with the best control were better off in terms of showing less progression of BM thickening. influence of intervention on renal structural changes. The treatment given during the interval between first and second The patients in this series have now been followed for 6 years after the first kidney biopsy. Follow-up study with determinabiopsy was either intensified diabetes control vs conventional control (Norway, n=20) or ACE inhibitors vs beta-blockers tion of AER, HbA 1c and blood pressure measurements have shown that BMT, HbA 1c and systolic blood pressure contrib-(Sweden, n=18). The analysis of follow-up biopsies has been completed only in the Norwegian series at the present time.
uted significantly to the variation in AER at 6 years. In the Swedish series the relationship between clinical variBoth series dealt with young (age, median and (range): 19 (14-29) years) patients with diabetes duration 12 (6-18) years ables during the years preceding the biopsy and the structural parameters was studied. It was found that 5-year mean and AER 33 (15-195) mg/min, i.e. the majority of patients had low-range albuminuria. No patient had elevated blood pres-HbA 1c , diabetes duration and GFR were the variables with an independent influence on the severity of the diabetic glosure at entry into the study. Non-diabetic kidney donors (ND) of age <40 years constituted the reference group. merulopathy [5] . In this series a comparison was also made with the course Since the aim was to compare change in structural data over a fairly short period of time (2-3 years) it was mandat-of GFR, estimated by determinations during the normoalbuminuric stage 2-5 years prior to the renal biopsy and again at ory to obtain the parameters with the highest possible precision. Therefore some effort has been made to optimize the the time of the biopsy. Patients showing a decline in GFR >5 ml /min/year had the thickest BM and matrix expansion. methodology. Estimation of mesangial volume fraction is especially demanding since the changes are only borderline at In multiple regression analysis of structure vs clinical variables the sole variable independently associated with the fall the early stage of diabetic nephropathy. Therefore, three levels were analysed in each of three glomeruli as the standard in GFR was BMT (P=0.003) [6 ] .
Thus, new little bits of information underline the procedure by electron microscopy (EM ) [1] . Further, in one of the series the measurements have been supplemented with association between diabetes control and the development of structural changes in the kidney and between structure and quantitation by light-microscopy (LM ) of 1-mm-thick sections, using the largest cross-sectional area of seven glomeruli function. The final analysis of the follow-up biopsies will show if treatment with ACE-inhibitors for 3 years has any in each case. Light-microscopy as expected led to higher Abstracts 1068 demonstrable effect on structural changes. Ongoing studies The concept of angiotensin II receptor blockers in hypertension and renal disease should further clarify if it holds true that morphometric studies are useful in intervention trials over short periods of time. 1997; 20: 265-271 to other angiotensin II antagonists, losartan has a uricosuric 6. Rudberg S, Østerby R. Decreasing glomerular filtration rate-effect which may be useful in patients with hypertension and an indicator of more advanced diabetic glomerulopathy in the hyperuricaemia. In hypertensive patients, the uricosuric effect early course of microalbuminuria in IDDM adolescents? Nephrol of losartan has been shown to prevent the diuretic-induced Dial Transplant 1997; 12: 1282 -1283 increase in plasma uric acid. Recently we have investigated the possible renal interaction between angiotensin II receptor antagonists and non-steroidal anti-inflammatory drugs (NSAID). Interestingly, although angiotensin II antagonists Renal interstitial expansion is modified by perindopril in true do not affect prostaglandin metabolism, we found that indomethacin blunts both the natriuretic response to the angiodiabetic glomerulosclerosis (DG in type 2 (NIDDM ) diabetic tensin II antagonist valsartan and to ACE inhibitor enalapril.
patients. A 2-year sequential biopsy study
Thus NSAID may also attenuate the blood pressure lowering Daniel J. Cordonnier, N. Pinel, C. Barro, Philippe Zaoui, on effect of angiotensin II receptor antagonists. Today the behalf of the DIABIOPSIES GROUP; CHU Grenoble, important remaining question concerns the renal protective France effects of angiotensin II receptor antagonists. Experimentally, angiotensin II blockers appear to have the same effect as ACE Angiotensin-converting enzyme inhibitors (ACE-I ) exert a inhibitors, but the final clinical response will be provided by protective effect against the progression of renal insufficiency the results of the renal study. in type 1 diabetes. Our objective was to study the structural effect of an ACEI, perindopril (PI ) in type 2 diabetic patients patients were randomized, 11 to PI and 11 to placebo (PO), 22: 339-347 after informed consent. At baseline (MO), 18 were macro and Burnier M, Hagman M, Nussberger J, Biollaz J, Armagnac C, 4 were microalbuminuric; diagnosis of DG (6 'early' and 16 Brouard R, Waeber B, Brunner HR. Short-term and sustained 'typical') was assessed by two pathologists; four pts were not renal effects of angiotensin II receptor blockade in healthy subjects. Hypertension 1995; 25: 602-609 included due to predominant ischaemic lesions. 1 patient ized method ) increased in PO (31.7%±5.3 to 40.5±11.6) and remained stable in PI (33.8%±4.8 to 34.6±6.6) (P<0.05). The relative volume of mesangium per glomerulus showed the same trend without reaching significance. Collagen VI, a marker of DG in man, was increased further in interstitium A follow-up study of the course of nephropathy in type 1 of PO than in those of PI (P<0.01); the same was observed diabetes with thrombospondin (P<0.01).
Ed Lewis; Section of Nephrology, Rush Presbyterian St, Conclusion. Despite limited patient population and observaLukes Medical Center, Chicago, USA tion time, renal biopsies advocate in this study for the role of angiotensin in interstitial expansion, a major factor of renal The purpose of the study was to determine the clinical course of type 1 diabetic nephropathy in patients randomized to two fibrosis. different levels of blood pressure control. 129 patients previ-Subjects and methods ously entered into our ACE inhibitor trial were randomized The analysis was performed in a subset of patients (n=35, 22 to intensive BP control (MAP 92 mmhg) or standard BP M/13 F ) who had microalbuminuria (10-100 mg/12 h in an control (MAP 100-107 mmHg). overnight urine sample) at randomization in a large doubleBaseline characteristics included 47% male; 97% white; age blind, placebo-controlled study, investigating the effect of 37 years; age of onset of type 1 DM 11 years; duration type 1 candesartan on blood glucose homeostasis and blood lipid DM 26 years; duration of proteinuria 7.4 years; duration of profile in patients with stable type 2 diabetes (aged 30-75 retinopathy 9.3 years; mean serum creatinine 1.7 mg/dl years, HbA 1c 5.5-9.0%), mild hypertension (sitting diastolic (150 pmol/l ); mean proteinuria 2.0 g/24h; iothalamate-GFR blood pressure 90-100 mmHg) and serum creatinine below 66 ml/min/1.73; glycosylated Hb 11.6%. Median dose of ram-150 mol/l for men and 120 mol/l for women. Patients were ipril in the standard group was 2.5 mg/day and the intensive randomized, after a 4-week placebo run-in period, to 12 group 10 mg/day. Median MAP achieved for the standard weeks double-blind treatment with candesartan 8-16 mg (n= group was 97 mmHg and the intensive group 90 mmHg. 15) or placebo (n=20) once daily. The differences between Median 24-h creatinine clearance in the standard group was treatments in change in efficacy variables from randomization 70 ml/min at baseline and 65 ml/min at 24 months follow-up. to the end of the study were analysed. Median creatinine clearance for the intensive group was 55.5 ml/min at baseline and 53.6 ml/min at 24 months followResults up. Median 24-h proteinuria was 1140 at baseline and 1723 mg/24 h at 24 months follow-up for the standard group Candesartan did not influence blood glucose homeostasis or and for the intensive group it was 1044 at baseline and blood lipid profile compared to placebo. The body weight 535 mg/24 h at 24 months follow-up.
remained unchanged in both treatment groups. The During the follow-up period the standard group experi-median urinary albumin excretion decreased from 28.5 to enced one serum creatinine doubling and 6 ESRD as com-12.2 mg/12 h (−57%) in patients treated with candesartan pared to the intensive group with one doubling and 3 ESRD.
(n=15) while it increased from 30.2 to 32.8 mg/12 h (+9%) We conclude: (1) ramipril is a renoprotective ACE inhib-in the placebo group (n=20, P=0.03 for the difference itor; (2) the combination of ramipril at higher dose level plus between treatments). In this subset of patients the mean MAP 92 mmHg is associated with regression of clinical reduction in the diastolic blood pressure was 6.4 mmHg in nephropathy; (3) half of the patients in the intensive BP con-the candesartan group and 3.6 mmHg in the placebo group trol group no longer meet criteria for overt clinical (P=NS ). nephropathy. respect [3, 4] . The more direct route of inhibiting the negative 2]: S37-S42 effects of angiotensin II by means of an angiotensin II recep-6. Goldberg AI, Dunlay MC, Sweet CS. Safety and tolerability of tor antagonist is expected to provide at least similar reduclosartan potassium, an angiotensin II receptor antagonist, tions of albuminuria [5] . This new class of drugs offer compared with hydrochlorthiazide, atenolol, felodipine ER, and therapeutic advantages like a reduction in the incidence of angiotensin-converting enzyme inhibitors for the treatment of systemic hypertension. Am J Cardiol 1995; 75: 793-795 cough and inflammation, seen with ACE inhibitors [6 ] . Candesartan is a new angiotensin II type 1 receptor antagonist with tight binding to and a slow dissociation from the receptor.
Conclusions
Advanced glycation end products and inhibitors Mark E. Cooper; Department of Medicine, University of Aim Melbourne, Austin & Repatriation Medical Centre, West Heidelberg 3081, Australia To assess the effect of candesartan on microalbuminuria in patients with type 2 diabetes and mild hypertension.
The process of advanced glycation involves a spontaneous of a specific endothelin receptor A antagonist on mRNA levels Diabetes 1995; 44: 895-899 1 expression in animal models of diabetes (reviewed in [4] ).
4. Wolf G, Ziyadeh F. The role of angiotensin II in diabetic
We recently found that serum TGF-b1 levels were reduced nephropathy: Emphasis on nonhemodynamic mechanisms. Am by captopril treatment in a small sample of patients who were 1997; 29: 1: 153-163 enrolled in the Collaborative study [13] , and the reduction of Proc Natl Acad Sci USA 1997; 94: was given orally in diabetic rats specifically inhibited the [9314] [9315] [9316] [9317] [9318] [9319] activation of PKC beta1 isoform without decreasing PKC 23. Kulkarni AB, Huh C-G, Becker D, Geiser A, Lyght M, Flanders alpha isoform activation. Glucose-induced increases in arach-KC, Roberts AB, Sporn MB, Ward JM, Karlsson S. idonic acid release, prostaglandin E2 production, and inhibiTransforming growth factor 1 null mutation in mice causes tion of Na+-K+ ATPase activities in the cultured mesangial excessive inflammatory response and early death. Proc Natl cells were completely prevented by the addition of LY333531.
J Kidney Dis
Acad Sci, USA 1993; 90: 770-774 Oral feeding of LY333531 prevented the increased mRNA expression of TGF-b1 and extracellular matrix components such as fibronectin and a1(IV ) collagen in the glomeruli of diabetic rats in parallel with inhibition of glomerular PKC Isozyme-specific inhibition of PKCb. LY333531 new activity. These results suggest that the activation of PKC, theraputic approaches to human disease by modulation of predominately the b isoform by hyperglycaemia in the mesprotein kinase C (PKC ) isozymes angial cells and glomeruli can partly contribute to early renal dysfunctions by alteration of prostaglandin production and Andreas Pfuetzner; George King, D. Kirk Ways, Michael R.
Na+-K+ ATPase activity as well as the chronic pathological Jirousek; Lilly Research Laboratories, Eli Lilly & Co. and changes by the overexpression of TGF-b1 and extracellular Joslin Diabetes Center, Harvard Medical School matrix components genes. Protein kinase C (PKC ) is a family of closely related serine These results taken in context suggest selective inhibition and threonine kinases. Overactivation of some PKC isozymes of the PKCb isozymes by LY333531 may offer a new has been postulated to occur in several diseases states includ-approach to address kidney disease as well as the microvascuing diabetic complications. Hyperglycaemia leads to over-lar complications and cardiomyopathy of diabetes [5] . activation of PKC and selectively to hyperactivation of PKCb through elevated diacylglycerol levels. Natl Acad Sci USA 1997: 94: 9320-9325 The stimulation of PKC activity by VEGF was preceded by the activation of phospholipase C gamma (PLCc). VEGF increased phosphatidylinositol 3-kinase activity 2.1-fold, which was inhibited by wortmannin, a phosphatidylinositol 3-kinase inhibitor, without decreasing the VEGF-induced Progression in inherited renal disease increase in PKC activity or endothelial cell growth. VEGF's Jean Pierre Grü nfeld, E. Plaisier, P. Jungers; Service de mitogenic effect was inhibited by LY333531, in a concentraNéphrologie, Hô pital Necker, 75015 Paris, France tion-dependent manner. In contrast, antisense PKCa oligonucleotides enhanced VEGF-stimulated cell growth with a The potential mechanisms of renal progression are diverse in simultaneous decrease of 70% in PKCa protein content. Thus the various inherited renal diseases: e.g. cyst progression and VEGF appears to mediate its mitogenic effects partly through compression of adjacent parenchyma in autosomal dominant the activation of the PLCc and PKC pathway, involving pre-polycystic kidney disease (ADPKD); persistence and extendominately PKCb isoform activation in endothelial cells.
sion of a1/a2 chains of type IV collagen in GBM, in the place A spectrum of biochemical and molecular abnormalities of a3/a4/a5 (IV ); focal segmental glomerulosclerosis in type I associated with chronic changes induced by glucose or dia-glycogen storage disease; glycolipid deposition, most particubetes in the cultured mesangial cells and renal glomeruli that larly in vessels, leading predominantly to ischaemic nephrocan be prevented by LY333531 [4] . Hyperglycaemia increased pathy in Fabry's disease. There is no single mechanism of DAG level in cultured mesangial cells exposed to high con-progression in inherited disorders. centrations of glucose and activated PKCa and b1 isozymes In ADPKD, two main determinants of progression have been identified: (1) PKD1 vs PKD2 disease, the renal progresin the renal glomeruli of diabetic rats. LY333531 added to sion being slower in the PKD2 type; interactions between The hypotheses which have formed the basis for studies of PKD1 and PKD2 genes have been recognized, and these may renal pathophysiology have rarely been 'competing'. Rather, be crucial to modulate the rate of progression. (2) The sex of they have invariably emerged as being complementary which the patient, the renal progression being slower in women. is not surprising in that the processes which cause disease are Among 126 ADPKD patients in ESRD at Necker, from 1989 almost always multifactorial in nature. Renal scarring is no to 1996, 42% were females; in the 26 patients in ESRD at 65 exception to this. years or more, 65% were females, and all 5 in ESRD at 70
The central issue in renal scarring, which is usually secondyears or more were female. Overall, women (n=53) were in ary to glomerular disease, is: Why does an acute insult not ESRD at 56+11 years and men (n=73) at 53.9+9 years. resolve but rather translate itself into a chronic destructive Low-protein diet, strict control of blood pressure, and ACE process? To answer this question it is useful to distinguish inhibition have been shown to have no significant effect on between (1) factors that per se are responsible for chronicity renal progression. However, the effects of earlier intervention i.e. the 'causes' of the scarring process, (2) factors that affect in the course of the disease have not been tested. the rate of scarring, and (3) factors which mediate the Alport syndrome is clinically and genetically heterogen-scarring process. eous. In X-linked disease (due to mutations of the gene encodHypotheses that address the 'cause of chronicity' must ing for a5 chain of type IV collagen), the rate of progression include the following: in males contrasts in juvenile-type ( EDRD <30 years) and adult-type (ESRD >30 years) families.
1. The initial injurious agent persists and causes chronic The rate of decline of creatinine clearance is also slower in damage. This could apply to diabetes but probably cannot the latter kindreds. No clear-cut relationship has been found be invoked in most primary glomerulopathies. so far between phenotype and genotype. The rate of progres-2. Chronic glomerular scarring is the result of haemosion is rapid in autosomal recessive disease (defects of a3 or dynamic adaptations that are set in train by the initial a4 (IV )). So far it has not been tested whether this rate is insult and which, if sufficiently severe, will destroy suffisimilar or not in female and male siblings from the same cient filtration surface area to cause the adaptation to be families. In anecdotal cases of Alport syndrome, ACE inhibipersistent in surviving glomeruli. The 'adaptation' thus tion has been claimed to be renoprotective, which would not becomes the injurious agent. be surprising in a primary glomerular disease. No prospective 3. Tubulointerstitial injury follows the initial glomerular study is available.
insult and it is this component that is self-perpetuating. The mechanisms of progression are unknown. Kalluri
For this hypothesis for be valid, there must be a link et al. have suggested that isoform switching (from a1/a2 to between the glomerular injury (or adaptation) and the a3/a4 (IV )) is developmentally arrested in X-linked Alport tubulointerstitial compartment, and injury to the latter disease. This defect would lead to increased susceptibility of must be irreversible and progressive. GBM to endoproteolysis. Glomerular accumulation of a1/a2
What causes tubulointerstitial injury associated with glom-(IV ) by itself could be deleterious. The molecular mechanism erular disease? The two principal ideas are that: of progression might be of great interest not only for Alport
(1) Filtration of proteins, lipids and other molecules injure syndrome, but also for other glomerular diseases.
the tubules and this sets up the scarring process. This is Similarly, the mechanism of progression of interstitial fibsupported by the recognition that the magnitude of prorosis in juvenile nephronophthisis, an autosomal recessive teinuria is a major predictor of the rate of progression disease, may provide interesting insight into more general and reversal of proteinuria slows progression. mechanisms of initiation and progression of interstitial (2) The 'chronic hypoxia hypothesis', which posits that the fibrosis.
same alterations in flow and pressure that affect the glom- The fact that some glomerular diseases progress even when Natl Acad Sci USA 1997; 94: 6965-6970 proteinuria is completely reversed or when blood pressure is Kashtan C, Michael AF. Alport syndrome. Kidney Int 1996; 50: well controlled must mean that these are not 'causes' of the [1145] [1146] [1147] [1148] [1149] [1150] [1151] [1152] [1153] [1154] [1155] [1156] [1157] [1158] [1159] [1160] [1161] [1162] [1163] progression but rather modulators of its rate.
Cohen EP, Lemann J Jr. In hereditary nephritis angiotensinconverting enzyme inhibition decreases proteinuria and may slow
The chronic hypoxia hypothesis critically requires that the rate of progression. Am J Kidney Dis 1996; 27: 199-203 interstitial microvessels be surrounded by cells which can Kalluri R, Shield CFI, Todd P et al. Isoform switching of type IV sense and respond to hypoxia once the scarring process has collagen is developmentally arrested in X-linked Alport syndrome been initiated. We have shown that human proximal tubular leading to increased susceptibility of renal basement membranes cells in culture produce cytokines in an oxygen-sensitive to endoproteolysis. J Clin Invest 1997; 99: 2470 -2478 manner (endothelin I, VEGF, TGFb). Others have shown that such cells also release chemokines that attract mononuclear cells which contribute to inflammation and scarring.
Competing hypothesis in renal scarring: further support for the
We have further shown that hypoxia is directly fibrogenic to chronic hypoxia hypothesis proximal tubular cells and renal interstitial fibroblasts which produce collagen, decrease their matrix metalloproteinase, Leon G. Fine, Chrystalla Orphanides, Jill T. Norman; Joint and increase their TIMP activities. Department of Medicine University College London and Royal Free Hospital Schools of Medicine, London, UK Because the fibrosing process per se obliterates microvessels, i.e. the 'healing of a scar', the hypoxia is per-dihydropyridine calcium-channel blockers (CCBs), verapamil and diltiazem, preserve renal morphology in a manner similar petuated and the parenchymal cells which are adjacent to to ACE inhibitors. This subclass of CCBs affects the synthesis such ischaemic areas respond by further collagen deposition of various matrix proteins such as heparan sulphate and gluand cytokine release. This in turn causes further microvascucoaminoglycan as well as fibroblast turnover [7] . Prevention lar loss and hypoxia and the process is self-perpetuating.
of mesangial expansion or glomerulosclerosis has not been The chronic hypoxia hypothesis therefore requires that a shown for either blockers or most dihydropyridine CCBs critical degree of initial hypoxic damage to the tubulointerstit- [3, 6 ] . ium is sufficient to set the vicious cycle in process. If the initial Dihydropyridine CCBs do not protect against morpholoinjury is not sufficiently severe, small or healing scars will gical progression of renal disease. Studies using 24-h blood result and the disease will not be progressive.
pressure monitoring in a rat model of renal insufficiency ranStudies are in progress which will establish how lowered domized animals to either a dihydropyridine, amlodipine, an oxygen tension triggers collagen production independently of ACE inhibitor, benazepril or a combination of each in a lower mediators such as TGF-b . The relevant molecules would be dose to achieve a similar level of blood pressure reduction. logical targets for interventional therapy.
Amlodipine did not reduce development of glomerulosclerosis or proteinuria, while the ACE inhibitor and the combination had similar benefits on these parameters [8] . This lack of protection by dihydropyridine CCBs is also Combination therapy for hypertension and renal disease in seen clinically and relates to a lack of effect on glomerular diabetes membrane permeability, in spite of blood-pressure reduction [9] . While, many factors may contribute to the disparate George L. Bakris; Rush University Hypertension Center, effects of the different subclasses of CCBs on both surrogate Rush-Presbyterian-St. Luke's Medical Center, Chicago, IL end-points as well as progression of renal disease, it is clear 60612, USA that arterial pressure reduction is the ultimate goal that uniMore than 75% of individuals with diabetes, microalbuminu-formly leads to preservation of renal function. Thus, since the ria and hypertension require two or more antihypertensive majority of patients with diabetic nephropathy require more medications to attain the newly recommended level of arterial than one medication to reduce arterial pressure, a combinapressure control, i.e.<130/85 mmHg [1] . To achieve this tion of antihypertensive agents, individually shown to reduce blood-pressure goal, it is common to add a medication whose arterial pressure and proteinuria as well as preserve renal antihypertensive action potentiates the initially selected drug morphology and function would be preferred. Since prelimin- [2] . To further improve compliance and reduce drug side ary evidence supports the notion that both ACE inhibitors effect profiles, fixed-dose combinations of antihypertensive and non-dihydropyridine CCBs slow progression of diabetic drugs with complementary modes of action have been renal disease to a greater extent than conventional blood recently developed [2] . These medications combine a lower pressure lowering agents, it is predicted that a combination of dose of two different antihypertensive drugs that, in a fixed these two classes of agents will provide better renal protection dose combination, reduce arterial pressure to a greater extent than either alone. Unfortunately, few animal or human studthan either alone.
ies have examined this hypothesis. While blood-pressure reduction is critical for the preservaOf the few animal studies that have evaluated the effects of tion of renal function, it is also important to select antihyper-an ACE inhibitor/CCB combination on various aspects of tensive agents that have unique effects on the kidney. Early renal disease, only one has actually controlled for bloodchanges observed in the diabetic kidney include an increase in pressure differences [9] . Thus a meaningful comparison efferent arteriolar tone and a loss of autoregulation. These cannot be made between the combination and its individual changes lead to an increase in intraglomerular capillary pres-components. As previously mentioned this study demonsure, which results in cell stretch and activation of various strated that combination therapy with a fixed-dose of an ACE autocrine and paracrine factors associated with tissue inhibitor, benazepril, and dihydropyridine CCB, amlodipine, injury [3] . In addition, glomerular membrane permeability is prevented progression to glomerulosclerosis seen with amlodincreased and microalbuminuria ensues, a surrogate marker ipine alone. It also reduced proteinuria to a greater extent for the presence and progression of diabetic nephropathy [3] . than amlodipine alone. However, the effects on proteinuria The earliest morphologic change is mesangial matrix expan-while greater than benazepril alone were not statistically sion and in some cases interstitial inflammation, the latter different. portends a poor renal prognosis [3, 4] .
In contrast to these findings, two animal studies that comExperimental evidence demonstrates that reductions in bined the effects of a non-dihydropyridine CCB with an ACE intraglomerular capillary pressure, through either profound inhibitor demonstrated a potentiation of the ACE inhibitor reductions in arterial pressure or dilation of the efferent art-associated reduction in proteinuria as well as relatively eriole, slow progression of diabetic renal disease [3, 5] . ACE greater preservation of renal morphology [5, 10] . These effects inhibitors reduce efferent arteriolar tone and intraglomerular were noted at similar levels of blood-pressure reduction. pressure. In clinical studies, ACE inhibitors demonstrate a Moreover, one of the two studies showed greater morpholoconsistent and persistent reduction in proteinuria as well as gical protection of the glomerulus, in the absence of bloodan attenuated progression of both type 1 and type 2 diabetes pressure control, using the fixed-dose combination of verapaassociated nephropathy [3, 6 ] . Moreover, while blood pres-mil with trandolopril in comparison to their individual sure reduction itself slows progression of early diabetic components [10] . The potentiating antiproteinuric effects of nephropathy, the ACE inhibitors appear to preserve renal a fixed-dose combination of verapamil and trandolopril, vs its function to an even greater extent than other agents [5, 6 ] do.
individual components, has also been observed in a recent Antihypertensive agents that do not reduce intraglomerular randomized clinical study of patients with type 2 diabetes pressure may still slow progression of diabetic nephropathy. associated nephropathy and comparable blood-pressure conThis may relate to their specific effects on synthesis or trol [11] .
Additionally, a 4-year follow-up study of patients with type degradation of mesangial matrix proteins. Notably, non-
